Molina Healthcare (NYSE:MOH) versus Mangoceuticals (NASDAQ:MGRX) Critical Contrast

Mangoceuticals (NASDAQ:MGRX) and Molina Healthcare (NYSE:MOH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Mangoceuticals and Molina Healthcare, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Molina Healthcare	2	11	3	1	2.18

Molina Healthcare has a consensus target price of $202.44, indicating a potential upside of 1.22%. Given Molina Healthcare’s stronger consensus rating and higher probable upside, analysts clearly believe Molina Healthcare is more favorable than Mangoceuticals.

Profitability

This table compares Mangoceuticals and Molina Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Molina Healthcare	-0.02%	3.73%	0.97%

Insider & Institutional Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 98.5% of Molina Healthcare shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 1.4% of Molina Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Mangoceuticals and Molina Healthcare”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460,000.00	17.42	-$20.64 million	($1.01)	-0.37
Molina Healthcare	$45.43 billion	0.23	$472.00 million	($0.18)	-1,111.11

Molina Healthcare has higher revenue and earnings than Mangoceuticals. Molina Healthcare is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mangoceuticals has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Molina Healthcare has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Summary

Molina Healthcare beats Mangoceuticals on 11 of the 15 factors compared between the two stocks.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

About Molina Healthcare

Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.